BFAR

Across TCGA pan-cancer cohorts, BFAR mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated BFAR data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher BFAR mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BFAR expression acts as an unfavorable survival marker.

LSCC and LUAD are the cancer types where BFAR mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Quartile	All	0.458	0.879	.019	5	view →
LUAD	DFS	Quartile	All	0.227	0.870	.016	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

BFAR–LSCC (OS)

Open the LSCC breakdown →